Genmab and AbbVie’s epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio’s Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood cancer transplant patients, BeOne Medicines’ BRUKINSA succeeds in a Phase 3 trial for chemotherapy-free frontline mantle cell lymphoma, and Vistagen’s fasedienol fails to meet its primary endpoint in a Phase 3 trial for social anxiety disorder: the most significant clinical trial results 3 July 2026 has to offer from across the pipeline.
This week delivered a mix of regulatory and clinical progress spanning hematology-oncology, cellular therapy, and neuropsychiatric drug development. The regulatory approval of a first-in-class cellular therapy stands out as the week’s most significant milestone, marking a genuine shift in how transplant physicians might manage one of the most feared long-term complications of stem cell transplantation. The remaining stories reflect a broader theme of B-cell malignancies moving toward chemotherapy-sparing regimens, alongside a reminder that promising neuroscience mechanisms do not always translate into confirmatory trial success. Here, Life Science Daily News brings you the most significant clinical trial results 3 July 2026.
Genmab and AbbVie’s Epcoritamab Meets Primary Endpoint in Phase 3 Trial for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Genmab announced on 29 June that its Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival compared with standard-of-care chemoimmunotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial compared fixed-duration, subcutaneously administered epcoritamab plus lenalidomide against rituximab plus gemcitabine and oxaliplatin (R-GemOx) in adult patients who had received at least one prior line of systemic therapy. Based on different censoring rules applied in the United States and outside the United States, the risk of disease progression or death was reduced by 60 per cent (hazard ratio 0.40, 95 per cent CI 0.30 to 0.55, p<0.0001) and 56 per cent (hazard ratio 0.44, 95 per cent CI 0.33 to 0.60, p<0.0001) respectively. The safety profile of the combination was consistent with the previously reported profiles of epcoritamab and lenalidomide individually.
EPCORE DLBCL-4 (NCT06508658) is a global, open-label, multi-centre trial that started on 13 August 2024 and remains ongoing. Epcoritamab is a bispecific antibody built on Genmab’s DuoBody technology, designed to bind simultaneously to CD3 on T-cells and CD20 on B-cells, directing T-cell-mediated killing of malignant B-cells. Already approved under the brand names Epkinly in the United States and Japan and Tepkinly in the European Union for certain lymphoma indications in more than 65 territories, epcoritamab is co-developed by Genmab and AbbVie as part of the companies’ broader oncology collaboration. Genmab and AbbVie plan to engage global regulatory authorities, and the full DLBCL-4 dataset will be submitted for presentation at a future medical meeting.
FDA Approves Orca Bio’s Tregzi as First Regulatory T-Cell Therapy to Reduce Chronic GVHD in Blood Cancer Transplant Patients
The FDA approved Tregzi (Orca Biosystems) on 30 June, the first regulatory T (Treg) cell-based immunotherapy indicated to improve chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Tregzi is a donor-derived cellular immunotherapy composed of purified hematopoietic stem and progenitor cells, Treg cells, and conventional T cells, each collected from the mobilised peripheral blood of an 8/8 HLA-matched related or unrelated donor. The approval was supported by the randomised PRECISION-T trial, which enrolled 187 adult patients with blood cancers including acute leukaemia and myelodysplastic syndrome, randomised to receive either Tregzi or a standard stem cell transplant. At one year, 78 per cent of Tregzi recipients achieved chronic GVHD-free survival compared with 38.4 per cent of patients who received a standard transplant, and after accounting for death as a competing risk, 12.6 per cent of Tregzi recipients developed serious chronic GVHD within one year compared with 44 per cent of the control arm.
Chronic GVHD occurs when transplanted donor immune cells attack the recipient’s own tissues, and it has long been one of the most difficult complications to prevent following stem cell transplantation for blood cancer. Side effects observed with Tregzi were generally consistent with those expected during stem cell transplantation, most commonly infections, with no severe infusion reactions and no cases of graft failure reported during the study period. Tregzi received both Orphan Drug and Regenerative Medicine Advanced Therapy designations from the FDA ahead of approval. The therapy, previously known as Orca-T, is indicated for use in matched-donor transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution in adults with hematological malignancies including acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome, and mixed-phenotype acute leukaemia.
BeOne Medicines’ BRUKINSA Succeeds in Phase 3 Trial for Chemotherapy-Free Frontline Mantle Cell Lymphoma
BeOne Medicines announced on 30 June positive topline results from the Phase 3 MANGROVE trial evaluating BRUKINSA (zanubrutinib) plus rituximab against bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma (MCL). At a prespecified interim analysis, the trial met its primary endpoint of progression-free survival as assessed by independent review committee, with the chemotherapy-free BRUKINSA-based regimen reducing the risk of progression or death by 43 per cent compared with standard chemoimmunotherapy (hazard ratio 0.57, 95 per cent CI 0.43 to 0.76, p<0.0001). The safety profile of BRUKINSA plus rituximab was consistent with the known safety profiles of both medicines, with no new safety signals identified. Overall survival, a key secondary endpoint, remained immature at the time of this analysis, though a trend favoured the BRUKINSA-based regimen.
MANGROVE (BGB-3111-306, NCT04002297) enrolled 510 patients across 176 sites worldwide and is the first global, randomised Phase 3 trial to evaluate a chemotherapy-free, rituximab maintenance-free regimen against standard-of-care chemoimmunotherapy in frontline MCL, an approach designed to spare patients approximately two years of infusions. In the experimental arm, patients received BRUKINSA 160 mg orally twice daily plus rituximab during the initial treatment period, followed by BRUKINSA monotherapy until disease progression or intolerance, while the control arm received bendamustine plus rituximab for six cycles. BRUKINSA is already approved in more than 80 markets and has been used to treat over 290,000 patients worldwide. BeOne is in discussions with global regulatory authorities, with submissions planned for the second half of 2026, and full efficacy and safety results will be presented at an upcoming medical meeting.
Vistagen’s Fasedienol Fails to Meet Primary Endpoint in Phase 3 Trial for Social Anxiety Disorder
Vistagen announced on 30 June that its Phase 3 PALISADE-4 trial of intranasal fasedienol did not meet its primary endpoint in the acute treatment of social anxiety disorder. In the overall trial population of 238 patients, fasedienol produced a least squares mean change from baseline on the Subjective Units of Distress Scale (SUDS) of -9.5 compared with -11.4 for placebo, a difference of 1.9 points that was not statistically significant (p=0.427). There was no treatment difference between fasedienol and placebo on any secondary endpoint. Safety and tolerability data were favourable and consistent with previous placebo-controlled trials of fasedienol.
In a post-hoc analysis of 123 patients with very severe social anxiety, defined by a baseline score of 95 or greater on the Liebowitz Social Anxiety Scale (LSAS), fasedienol showed a nominally statistically significant improvement over placebo, with a difference in least squares means of 9.1 points (p=0.036). Based on the totality of data from the fasedienol programme, Vistagen plans to shift its regulatory strategy away from acute, single-dose treatment of social anxiety symptoms and toward a registrational pathway centred on the LSAS as a primary endpoint. The company intends to meet with the FDA to discuss a potential path forward supported by a single future multi-dose Phase 3 trial, informed by the FDA’s June 2026 draft guidance on demonstrating substantial evidence of effectiveness, together with confirmatory evidence from the earlier, positive PALISADE-2 trial.
Looking Ahead
This week’s clinical trial results 3 July 2026 illustrate a pipeline moving in two directions at once: meaningful, incremental progress in B-cell malignancies alongside a reminder that neuropsychiatric drug development remains stubbornly difficult to predict. The FDA’s approval of Tregzi marks a genuine advance for transplant medicine, offering physicians a new tool to protect patients from one of the most feared long-term complications of allogeneic stem cell transplantation. Genmab and BeOne’s respective Phase 3 successes both point toward a future of chemotherapy-sparing regimens for B-cell lymphomas, potentially easing the treatment burden for thousands of patients. Vistagen’s setback in PALISADE-4, tempered by a promising signal in patients with the most severe social anxiety disorder, underscores how difficult it remains to translate early efficacy signals into confirmatory trial success. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 3 July 2026 that matter most across the global life sciences pipeline.
This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently.
All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions
